Atrial Fibrillation
Featured Article
Blake Charlton, MD a clinical fellow at the University of California, San Francisco School of Medicine, discusses his recent study that examined how NOACs and warfarin impact patients with atrial fibrillation differently.
Researchers recently examined the safety and efficacy of apixaban for anticoagulation in patients with atrial fibrillation scheduled for cardioversion.
A drug is associated with an increased risk of mortality among patients with atrial fibrillation with and without heart failure, recent research suggests.